Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TFFP - TFF Pharmaceuticals, Inc.
Market Cap 15.86M P/E - EPS this Y 63.90% Ern Qtrly Grth -
Income -19.39M Forward P/E -0.73 EPS next Y 11.90% 50D Avg Chg -
Sales 1.2M PEG - EPS past 5Y - 200D Avg Chg -53.00%
Dividend N/A Price/Book 0.96 EPS next 5Y - 52W High Chg -94.00%
Recommedations 2.00 Quick Ratio 1.32 Shares Outstanding 3.47M 52W Low Chg 37.00%
Insider Own 3.31% ROA -105.91% Shares Float 2.76M Beta 1.36
Inst Own 22.49% ROE -213.51% Shares Shorted/Prior 149.04K/144.33K Price 0.44
Gross Margin - Profit Margin - Avg. Volume 178,832 Target Price 30.00
Oper. Margin -609.42% Earnings Date Nov 12 Volume 109,268 Change 4.05%
Healthcare | Biotechnology | United States
About TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

TFF Pharmaceuticals, Inc. News
11/14/24 TFF Pharmaceuticals Announces It Will Wind Down Operations
10/08/24 TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
09/26/24 TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
09/11/24 TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
09/10/24 TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
09/03/24 TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/17/24 TFF Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
08/14/24 TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
08/14/24 TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
08/06/24 TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
06/26/24 TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
06:00 AM TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
06/19/24 3 52-Week-Low Losers Ready to Become Big-Time Stock Winners
05/23/24 TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
05/20/24 TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
05/15/24 TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
05/14/24 TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
05/14/24 TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
05/01/24 TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
04/29/24 TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
CARLSON CAPITAL L P 10% Owner 10% Owner Aug 15 Sell 0.41 216,000 88,560 5,064,000 08/17/23
Weisman Harlan F President and CEO President and CEO Aug 15 Buy 0.25 600,000 150,000 814,615 08/15/23
ROCAMBOLI STEPHEN Director Director Aug 15 Buy 0.25 20,000 5,000 36,000 08/15/23
Roberts Brandi Director Director Aug 15 Buy 0.25 20,000 5,000 20,000 08/15/23
COLEMAN KIRK ALLEN Chief Financial Offi.. Chief Financial Officer Aug 15 Buy 0.25 20,000 5,000 35,675 08/15/23
MILLS ROBERT S Director Director Aug 15 Buy 0.25 40,000 10,000 55,980 08/15/23
Mikhak Zamaneh Chief Medical Office.. Chief Medical Officer Aug 15 Buy 0.25 120,000 30,000 135,000 08/15/23
COLEMAN KIRK ALLEN Chief Financial Offi.. Chief Financial Officer Mar 10 Buy 0.7881 12,000 9,457 15,675 03/13/23
Weisman Harlan F President and CEO President and CEO Mar 10 Buy 0.8789 150,000 131,835 214,615 03/13/23
Mikhak Zamaneh Chief Medical Office.. Chief Medical Officer Mar 10 Buy 0.82 15,000 12,300 15,000 03/13/23
Weisman Harlan F President and CEO President and CEO Dec 15 Buy 1.06 50,000 53,000 64,615 12/19/22
Fletcher Aaron G.L. Director Director Nov 22 Buy 1.15 43,470 49,990 143,470 11/23/22
Weisman Harlan F Director Director May 18 Buy 5.31 7,115 37,781 14,615 05/20/22
Fletcher Aaron G.L. Director Director May 16 Buy 4.97 109,600 544,712 109,600 05/17/22
Weisman Harlan F Director Director May 16 Buy 4.74 2,500 11,850 7,500 05/17/22
COLEMAN KIRK ALLEN Chief Financial Offi.. Chief Financial Officer May 16 Buy 4.62 1,675 7,738 3,675 05/17/22
Mattes Glenn R. President and CEO President and CEO May 16 Buy 4.78 16,000 76,480 36,000 05/17/22
ROCAMBOLI STEPHEN Director Director May 16 Buy 4.54 3,000 13,620 18,722 05/17/22
Fletcher Aaron G.L. Director Director Apr 04 Buy 6.66 542,000 3,609,720 542,000 04/04/22